These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

358 related items for PubMed ID: 18223462

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Influence of Proton Pump Inhibitors on Mycophenolic Acid Pharmacokinetics in Patients With Renal Transplantation and the Relationship With Cytochrome 2C19 Gene Polymorphism.
    Ciftci HS, Karadeniz MS, Tefik T, Caliskan Y, Yazıcı H, Demir E, Turkmen A, Nane I, Oguz FS, Aydin F.
    Transplant Proc; 2017 Apr; 49(3):490-496. PubMed ID: 28340819
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Effect of lansoprazole and rabeprazole on tacrolimus pharmacokinetics in healthy volunteers with CYP2C19 mutations.
    Itagaki F, Homma M, Yuzawa K, Nishimura M, Naito S, Ueda N, Ohkohchi N, Kohda Y.
    J Pharm Pharmacol; 2004 Aug; 56(8):1055-9. PubMed ID: 15285851
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. No relevant pharmacokinetic interaction between pantoprazole and mycophenolate in renal transplant patients: a randomized crossover study.
    Rissling O, Glander P, Hambach P, Mai M, Brakemeier S, Klonower D, Halleck F, Singer E, Schrezenmeier EV, Dürr M, Neumayer HH, Budde K.
    Br J Clin Pharmacol; 2015 Nov; 80(5):1086-96. PubMed ID: 25913040
    [Abstract] [Full Text] [Related]

  • 8. Influence of cytochrome P450 (CYP) 3A5 polymorphisms on the pharmacokinetics of lansoprazole enantiomers in CYP2C19 extensive metaboliser renal transplant recipients.
    Miura M, Inoue K, Satoh S, Itoh Y, Kagaya H, Tada H, Tanaka Y, Habuchi T, Suzuki T.
    Clin Drug Investig; 2007 Nov; 27(4):251-8. PubMed ID: 17358097
    [Abstract] [Full Text] [Related]

  • 9. Differences in clearance of mycophenolic acid among renal transplant recipients, hematopoietic stem cell transplant recipients, and patients with autoimmune disease.
    de Winter BC, Mathot RA, Sombogaard F, Neumann I, van Hest RM, Doorduijn JK, van Gelder T.
    Ther Drug Monit; 2010 Oct; 32(5):606-14. PubMed ID: 20720518
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Unexpected augmentation of mycophenolic acid pharmacokinetics in renal transplant patients receiving tacrolimus and mycophenolate mofetil in combination therapy, and analogous in vitro findings.
    Zucker K, Rosen A, Tsaroucha A, de Faria L, Roth D, Ciancio G, Esquenazi V, Burke G, Tzakis A, Miller J.
    Transpl Immunol; 1997 Sep; 5(3):225-32. PubMed ID: 9402690
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Pharmacokinetics, efficacy, and safety of mycophenolate mofetil in combination with standard-dose or reduced-dose tacrolimus in liver transplant recipients.
    Nashan B, Saliba F, Durand F, Barcéna R, Herrero JI, Mentha G, Neuhaus P, Bowles M, Patch D, Bernardos A, Klempnauer J, Bouw R, Ives J, Mamelok R, McKay D, Truman M, Marotta P.
    Liver Transpl; 2009 Feb; 15(2):136-47. PubMed ID: 19177449
    [Abstract] [Full Text] [Related]

  • 17. The role of proton pump inhibitors on early mycophenolic acid exposure in kidney transplantation: evidence from the CLEAR study.
    Kiberd BA, Wrobel M, Dandavino R, Keown P, Gourishankar S.
    Ther Drug Monit; 2011 Feb; 33(1):120-3. PubMed ID: 21192310
    [Abstract] [Full Text] [Related]

  • 18. A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens.
    Dösch AO, Ehlermann P, Koch A, Remppis A, Katus HA, Dengler TJ.
    Clin Ther; 2006 Jun; 28(6):893-905. PubMed ID: 16860172
    [Abstract] [Full Text] [Related]

  • 19. Interleukin-1beta genetic polymorphism influences the effect of cytochrome P 2C19 genotype on the cure rate of 1-week triple therapy for Helicobacter pylori infection.
    Take S, Mizuno M, Ishiki K, Nagahara Y, Yoshida T, Inaba T, Yamamoto K, Okada H, Yokota K, Oguma K, Shiratori Y.
    Am J Gastroenterol; 2003 Nov; 98(11):2403-8. PubMed ID: 14638340
    [Abstract] [Full Text] [Related]

  • 20. A prospective analysis of the effects of enteric-coated mycophenolate sodium and mycophenolate mofetil co-medicated with a proton pump inhibitor in kidney transplant recipients at a single institute in China.
    Xu L, Cai M, Shi BY, Li ZL, Li X, Jin HL.
    Transplant Proc; 2014 Jun; 46(5):1362-5. PubMed ID: 24935300
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.